Search results
Results from the WOW.Com Content Network
In 1979 a new edition was published with a new title, The Pharmaceutical Codex. The Medicines Commission had recommended in 1972 that the British Pharmacopoeia should henceforth be the only compendium of official standards for medicines in the UK, and the BPC lost its status as an official book. The PSGB remained as the publishers.
The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom.It is an annually published collection of quality standards for medicinal substances in the UK, which is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing.
It is published by Wiley-Blackwell on behalf of the Royal Pharmaceutical Society. It is an official journal of the British Pharmaceutical Conference. It was established in 1870 and acquired its current title in 1949. The editor-in-chief is D. Jones (Queen's University Belfast).
A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). [1] The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming ...
The Commission on Human Medicines (CHM) is a committee of the UK's Medicines and Healthcare products Regulatory Agency.It was formed in October 2005, and assumed the responsibilities of the Medicines Commission and the Committee on Safety of Medicines.
The Society was founded in 1931, in Oxford, by a group of about 20 pharmacologists. [3] They were brought together on the initiative of Professor James Andrew Gunn, through a letter signed by Gunn, Henry H. Dale, and Walter E. Dixon, and sent to the heads of university departments of pharmacology and of institutions for pharmacological research in Great Britain, with proposals for the ...
The MHRA and the US Food and Drug Administration were criticised in the 2012 book Bad Pharma, [43] and in 2004 by David Healy in evidence to the House of Commons Health Committee, [44] for having undergone regulatory capture, i.e. advancing the interests of the drug companies rather than the interests of the public.
The Royal Pharmaceutical Society was founded on 15 April 1841 as the Pharmaceutical Society of Great Britain, and headquartered at 17 Bloomsbury Square, London. Among its founding members were Jacob Bell and William Allen. The Northern British (Scottish) branch began the same year with nine founders including William Flockhart and John Duncan. [3]